coronavirus delivered via a nasal spray will enter human studies in Hong Kong next month, a top infectious diseases doctor said.The early-stage clinical trial will enroll about 100 adults, said Yuen Kwok-Yung, chair of infectious diseases in the University of Hong Kong’s department of microbiology.
The candidate vaccine is similar to a nasal spray flu immunization already on the market that’s designed to start working where respiratory viruses typically enter the body: the nose.“Our idea is that we want both influenza and Covid-19 protection at the same time," Yuen said in an interview.Research on the experimental spray received funding from the Coalition for Epidemic Preparedness Innovations in Norway and Hong Kong’s government, and will.